

Innovation all for the patients



Roche A member of the Roche group

## Roche Announces Updates on Alecensa for Adjuvant Therapy in ALK-Positive Early-Stage Non-Small Cell Lung Cancer

TOKYO, October 18, 2023 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced today that Roche issued a press release regarding results of a phase III clinical trial (ALINA study) for anti-cancer agent/ALK inhibitor Alecensa® (alectinib) for adjuvant therapy in ALK-positive early-stage non-small cell lung cancer.

Please refer to the link below for details of the press release:

Roche's Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer

<https://www.roche.com/media/releases/med-cor-2023-10-18>

###